Company Overview
Beam Therapeutics Inc. operates as a biotechnology company dedicated to developing precision genetic medicines for patients suffering from serious diseases within the United States. Its core portfolio focuses on hematology and genetic diseases, featuring specific programs like Ristoglogene autogetemcel, which represents a patient-specific, autologous hematology treatment approach. The company functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself to address significant unmet medical needs through advanced genetic interventions. With a market capitalization of $2.51B and annual revenue of $139.74M, Beam Therapeutics maintains a substantial enterprise scale supported by an employee base of 511 individuals. These valuation and revenue figures indicate that the company holds a significant position within its niche, leveraging a large cash reserve to fund its extensive research and development initiatives without immediate reliance on external financing for daily operations.
Financial Health
Beam Therapeutics reported a revenue of $139.74M for the trailing twelve months, yet this generated a net income of -$79,992,000 and an EBITDA of -$361,399,008, revealing a substantial gap between top-line growth and profitability driven by high operational costs. The company's free cash flow stands at -$220,311,120, indicating that current operations consume cash faster than it is generated, which reflects the capital-intensive nature of biotechnology development rather than immediate financial distress. The gross margin is reported at -193.1%, the operating margin at -15.3%, and the profit margin at -57.2%; these negative figures collectively indicate that the company is currently operating at a loss where costs significantly exceed revenue across all tiers of profitability. In terms of leverage, the company holds $1.25B in cash against $154.12M in debt, resulting in a debt-to-equity ratio of 12.45, which suggests a balance sheet that is heavily weighted toward cash assets rather than traditional interest-bearing liabilities. The current ratio of 13.09 demonstrates exceptionally strong short-term liquidity, providing ample coverage for current liabilities and ensuring operational continuity. Return on Equity is -8.1% and Return on Assets is -18.6%, metrics that reveal management is currently deploying capital to generate losses, a common characteristic in early-stage growth phases where reinvestment outweighs immediate return generation.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, while the forward P/E is -5.70, a divergence that implies the market prices the stock based on future expectations despite current unprofitability. The price-to-book ratio is 1.97, indicating that the market values the company at nearly twice its book value, suggesting a premium assigned to its intellectual property and potential future cash flows. Alternative valuation metrics such as the price-to-sales ratio of 17.95 and an EV/EBITDA of -3.75 suggest that investors are valuing the company primarily on its revenue generation capabilities and growth trajectory rather than current earnings power. The 52-week high is $36.44 and the 52-week low is $13.53, providing a range within which the stock has traded; without a specific current price input to calculate the exact percentage, the stock's position is defined by this wide volatility band. The beta of 2.17 indicates that the stock exhibits high price volatility relative to the broader market, moving more than twice as much as the overall index during periods of market fluctuation.
Growth & Income
Beam Therapeutics demonstrated a revenue growth of 279.5% year-over-year, while earnings growth is listed as N/A due to the absence of net income, implying that top-line expansion is occurring without immediate profitability. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available earnings are retained and reinvested into growth initiatives rather than distributed to shareholders. This non-dividend profile is typical for biotechnology firms that prioritize funding clinical trials and product development over income generation for investors. Consequently, the overall growth and income profile for Beam Therapeutics is characterized by aggressive revenue expansion and zero current income distribution, relying entirely on future potential to realize returns.